サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794484

モノ・ワクチンの世界市場

Mono Vaccines

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
モノ・ワクチンの世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

モノ・ワクチンの世界市場は2030年までに122億米ドルに達する見込み

2024年に102億米ドルと推定されるモノ・ワクチンの世界市場は、2024年から2030年にかけてCAGR 3.0%で成長し、2030年には122億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである髄膜炎菌ワクチンは、CAGR 3.3%を記録し、分析期間終了時には52億米ドルに達すると予測されます。日本脳炎ワクチン分野の成長率は、分析期間中CAGR 3.6%と推定されます。

米国市場は28億米ドル、中国はCAGR 5.8％で成長すると予測

米国のモノ・ワクチン市場は、2024年には28億米ドルになると推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.8%として、2030年までに24億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.3%と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界のモノ・ワクチン市場- 主要動向と促進要因のまとめ

現代の予防接種戦略においてモノ・ワクチンが依然として重要なのはなぜか？

単一の病原体に対する予防接種を目的としたモノ・ワクチンは、依然として世界の予防接種プログラムに不可欠な要素です。これらのワクチンは、定期的な予防接種スケジュールにも、公衆衛生キャンペーンにも広く使用されています。特に幼児期の予防接種、渡航医学、特定の疾病の予防が必要とされるアウトブレイク対策において、その重要性は明らかです。一般的なモノ・ワクチンには、麻疹、B型肝炎、インフルエンザ、破傷風、狂犬病などがあります。

モノ・ワクチンは、免疫系を同時に複数の抗原にさらすことなく、正確な防御を提供します。これは、曝露後の予防や、患者の病歴、アレルギー、禁忌に基づいた予防接種など、特定の臨床状況において特に重要です。保健当局は、段階的な予防接種スケジュール、ブースター投与、疾病撲滅活動における標的を絞った介入において、引き続きモノ・ワクチンに依存しています。

技術はモノ・ワクチンの開発と生産にどのような影響を与えているか？

ワクチン開発における技術の進歩は、モノ・ワクチンの安全性、安定性、有効性を向上させました。最新の製造技術には、組換えDNA技術、ウイルス様粒子プラットフォーム、mRNAベースの開発などがあり、これらはすべて免疫反応の改善と副作用の軽減に寄与しています。アジュバントやデリバリーシステムの革新も、抗原提示や長期免疫を強化しています。

コールドチェーンの最適化と凍結乾燥製剤は、低資源環境におけるモノ・ワクチンの物流面での実行可能性を高めています。投与量の標準化や、マイクロニードルパッチや経口ワクチンのような針を使わない投与方法も、コンプライアンスや投与の簡便性を向上させるために開発されています。バイオ製造における細胞培養生産と自動化の利用の増加は、効率的かつコスト効率よく生産を拡大するのに役立っています。

需要が高まっている場所と主なエンドユーザーは？

モノ・ワクチンの需要は、小児ヘルスケア、旅行医療、公衆衛生アウトリーチ、動物用アプリケーションで増加しています。先進国、発展途上国を問わず、国家的な予防接種プログラムには、公衆衛生上の脅威となる病気に対するモノ・ワクチンが含まれています。アウトブレイクが発生した地域では、モノ・ワクチンが迅速に配備され、病気の蔓延を抑え、脆弱な人々を守ります。

病院、診療所、政府衛生局が主なエンドユーザーであり、疾病対策キャンペーンを実施している非政府組織も同様です。旅行者や医療従事者は、地域の疾病リスクに特化したモノ・ワクチンを必要とします。獣医学では、モノ・ワクチンは家畜やコンパニオンアニマルの個々の疾病を予防するために使用され、動物の福祉と食の安全を支えています。

モノ・ワクチン市場の成長を促進する要因は？

モノ・ワクチン市場の成長は、疾病の持続的な蔓延、的を絞った予防接種に対する規制の焦点、柔軟な予防接種オプションの必要性など、いくつかの要因によって牽引されています。麻疹、肝炎、狂犬病などの疾病の発生は、迅速な単一抗原による予防接種の需要を支え続けています。疾患固有のリスクに対する意識の高まりや成人予防接種プログラムの拡大も成長に寄与しています。

ワクチン設計の技術的進歩、より効率的な製造方法、官民の協力体制が、手頃な価格で効果的なワクチンへの幅広いアクセスを支えています。特定の感染症の撲滅に焦点を当てたプログラムも、単ワクチンの展開に大きく依存しています。ヘルスケアシステムが精密な予防接種と曝露後の管理を重視する中、モノ・ワクチンは世界のワクチンポートフォリオの中で確固たる地位を維持すると予想されます。

セグメント

タイプ別（髄膜炎菌ワクチン,日本脳炎ワクチン,肝炎ワクチン,黄熱ワクチン,その他）

調査対象企業の例

  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Biological E Limited
  • CanSino Biologics Inc.
  • CSL Seqirus（CSL Limited）
  • Daiichi Sankyo Co., Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc（GSK）
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd
  • Pfizer Inc.
  • Sanofi Pasteur（Sanofi S.A.）
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Valneva SE
  • VBI Vaccines Inc.
  • Zydus Lifesciences Ltd.（Zydus Cadila）

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールで市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37431

Global Mono Vaccines Market to Reach US$12.2 Billion by 2030

The global market for Mono Vaccines estimated at US$10.2 Billion in the year 2024, is expected to reach US$12.2 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Meningococcal Vaccine, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$5.2 Billion by the end of the analysis period. Growth in the Japanese Encephalitis Vaccine segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 5.8% CAGR

The Mono Vaccines market in the U.S. is estimated at US$2.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Mono Vaccines Market - Key Trends & Drivers Summarized

Why Are Mono Vaccines Still Relevant in Modern Immunization Strategies?

Mono vaccines, which are designed to immunize against a single pathogen, remain an essential component of global vaccination programs. These vaccines are widely used in both routine immunization schedules and targeted public health campaigns. Their relevance is especially clear in early childhood immunization, travel medicine, and outbreak control where specific disease protection is required. Common mono vaccines include those for measles, hepatitis B, influenza, tetanus, and rabies.

Mono vaccines offer precise protection without exposing the immune system to multiple antigens simultaneously. This is particularly important in certain clinical situations, such as post-exposure prophylaxis or when tailoring immunization based on patient history, allergies, or contraindications. Health authorities continue to rely on mono vaccines for phased immunization schedules, booster doses, and targeted interventions in disease elimination efforts.

How Is Technology Influencing Mono Vaccine Development and Production?

Technological advancements in vaccine development have improved the safety, stability, and effectiveness of mono vaccines. Modern production techniques include recombinant DNA technology, virus-like particle platforms, and mRNA-based development, all of which contribute to improved immune response and reduced side effects. Innovations in adjuvants and delivery systems are also enhancing antigen presentation and long-term immunity.

Cold chain optimization and lyophilized formulations have increased the logistical viability of mono vaccines in low-resource settings. Standardization in dosage and needle-free delivery options, such as microneedle patches and oral vaccines, are also being developed to improve compliance and ease of administration. Increasing use of cell-culture production and automation in biomanufacturing is helping scale up production efficiently and cost-effectively.

Where Is Demand Rising and Who Are the Primary End Users?

Demand for mono vaccines is increasing in pediatric healthcare, travel medicine, public health outreach, and veterinary applications. National immunization programs across both developed and developing countries include mono vaccines for diseases that still pose public health threats. In areas where outbreaks occur, mono vaccines are rapidly deployed to control disease spread and protect vulnerable populations.

Hospitals, clinics, and government health departments are the primary end users, alongside non-governmental organizations running disease control campaigns. Travelers and healthcare workers often require mono vaccines specific to regional disease risks. In veterinary medicine, mono vaccines are used to prevent individual diseases in livestock and companion animals, supporting both animal welfare and food safety.

What Factors Are Driving Growth In The Mono Vaccines Market?

Growth in the mono vaccines market is driven by several factors including persistent disease burdens, regulatory focus on targeted immunization, and the need for flexible vaccination options. Outbreaks of diseases such as measles, hepatitis, and rabies continue to sustain demand for rapid, single-antigen immunization. Rising awareness about disease-specific risks and expansion of adult immunization programs are also contributing to growth.

Technological progress in vaccine design, more efficient production methods, and public-private collaborations are supporting broader access to affordable and effective mono vaccines. Programs focused on eliminating specific infectious diseases also depend heavily on mono vaccine deployment. As healthcare systems emphasize precision immunization and post-exposure management, mono vaccines are expected to maintain a strong position within global vaccine portfolios.

SCOPE OF STUDY:

The report analyzes the Mono Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine, Other Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Biological E Limited
  • CanSino Biologics Inc.
  • CSL Seqirus (CSL Limited)
  • Daiichi Sankyo Co., Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd
  • Pfizer Inc.
  • Sanofi Pasteur (Sanofi S.A.)
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Valneva SE
  • VBI Vaccines Inc.
  • Zydus Lifesciences Ltd. (Zydus Cadila)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mono Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Targeted Immunization Strategies Propels Demand for Mono Vaccines
    • Increasing Prevalence of Preventable Infectious Diseases Strengthens Use of Single-Antigen Vaccines
    • Expansion of National Immunization Programs Drives Procurement of Mono Vaccines for Mass Administration
    • Demand for Simplified Dosing and Lower Reactogenicity Supports Growth in Mono Vaccine Adoption
    • Global Push for Measles and Polio Eradication Sustains Long-Term Demand for Disease-Specific Vaccines
    • Growing Preference for Controlled Immune Response Fuels Use of Mono Vaccines in Pediatric Applications
    • Advancements in Antigen Isolation and Stabilization Enhance Efficacy of Mono Vaccine Formulations
    • Demand from Immunocompromised Patient Populations Spurs Use of Targeted Single-Disease Vaccines
    • Increasing R&D in Emerging Diseases Strengthens Market for Rapid-Response Mono Vaccine Platforms
    • Expansion of Cold Chain Infrastructure in Developing Regions Enables Wider Access to Single-Antigen Vaccines
    • Integration into Routine Childhood Vaccination Schedules Ensures Steady Public Sector Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mono Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Meningococcal Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Meningococcal Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Meningococcal Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Japanese Encephalitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Japanese Encephalitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Japanese Encephalitis Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatitis Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Yellow Fever Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Yellow Fever Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Yellow Fever Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • JAPAN
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • CHINA
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: China 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • EUROPE
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Mono Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • FRANCE
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: France 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • GERMANY
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Mono Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • INDIA
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: India 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Mono Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Mono Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
  • AFRICA
    • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030

IV. COMPETITION